TRL-345

Recently added to the BioPortfolio report store, Trellis Bioscience, Inc. - Product Pipeline Review - 2015 is a new report from Global Markets Direct published on 2015-07-14. This 28-page report is available in PDF from $1500. Trellis Bioscience, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Trellis Bioscience, Inc. - Product Pipeline Review - 2015’, provides an overview of the Trellis Bioscience, Inc.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Trellis Bioscience, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Trellis Bioscience, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Trellis Bioscience, Inc.’s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Trellis Bioscience, Inc.’s pipeline products Reasons to buy - Evaluate Trellis Bioscience, Inc.’s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Trellis Bioscience, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Trellis Bioscience, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Trellis Bioscience, Inc. and exploit collaboration and partnership opportunities - Identify emerging… Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Trellis Bioscience, Inc. Snapshot 5 Trellis Bioscience, Inc. Overview 5 Key Information 5 Key Facts 5 Trellis Bioscience, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Trellis Bioscience, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Trellis Bioscience, Inc. - Pipeline Products Glance 14 Trellis Bioscience, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Trellis Bioscience, Inc. - Drug Profiles 16 Monoclonal Antibody To Antagonize HER-3 for Cancer 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 TRL-345 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Monoclonal Antibodies for Group A Streptococcus Infections 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Monoclonal Antibodies for Rabies 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Monoclonal Antibody 1 for Bacterial Infections 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Monoclonal Antibody 2 for Bacterial Infections 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Trellis Bioscience, Inc. - Pipeline Analysis 22 Trellis Bioscience, Inc. - Pipeline Products by Target 22 Trellis Bioscience, Inc. - Pipeline Products by Molecule Type 23 Trellis Bioscience, Inc. - Pipeline Products by Mechanism of Action 24 Trellis Bioscience, Inc. - Recent Pipeline Updates 25 Trellis Bioscience, Inc. - Locations And Subsidiaries 26 Head Office 26 Appendix 27 Methodology 27 Coverage 27 Secondary Research 27 Primary Research 27 Expert Panel Validation 27 Contact Us 27 Disclaimer 28 For more information open Trellis Bioscience, Inc. - Product Pipeline Review - 2015. SKU: GMDHC07298CDB